News FDA experts back Novo Nordisk's key diabetes drug Novo hopes for blockbuster sales from semaglutide
News Automatic artificial pancreas shows promise in trial Experimental device requires no user input at all.
News J&J hopes FDA cardio label will limit Invokana damage Diabetes drug has been hit by amputation warning on label.
News No cardio protection indication for Novo's semaglutide - yet Danish pharma plans outcome trial to confirm benefits in SUSTAIN 6
News ADARx, Trex, and Retension take aim at IPOs The appetite among biotechs for IPOs shows no signs of being satisfied, with three more – ADARx, TRex, and Retension – making their intentions known.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
